Inspire Medical Systems, Inc. (INSP) Bundle
A Brief History of Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc., founded in 2007, has established itself as a leader in the field of sleep apnea treatment. The company is renowned for its innovative Inspire therapy, a surgically implanted device that stimulates the hypoglossal nerve to prevent airway obstruction during sleep.
Financial Performance Overview
As of September 30, 2024, Inspire Medical Systems reported significant financial growth. The total revenue for the three months ended September 30, 2024, was $203.2 million, representing a 32.5% increase from $153.3 million in the same period of 2023.
| Period | Total Revenue (in thousands) | Net Income (in thousands) | Gross Margin (%) |
|---|---|---|---|
| Q3 2024 | $203,191 | $18,497 | 84.1% |
| Q3 2023 | $153,302 | $(8,540) | 84.1% |
| 9M 2024 | $563,086 | $18,285 | 84.5% |
| 9M 2023 | $432,291 | $(35,916) | 84.1% |
Revenue Breakdown
In the third quarter of 2024, U.S. revenue accounted for $195.8 million, a 32.8% increase year-over-year, while international revenues rose to $7.4 million, marking a 27.2% increase.
| Region | Q3 2024 Revenue (in thousands) | Q3 2023 Revenue (in thousands) | Change (%) |
|---|---|---|---|
| United States | $195,828 | $147,514 | 32.8% |
| International | $7,363 | $5,788 | 27.2% |
Research and Development Investments
Inspire Medical Systems has consistently invested in research and development to enhance its product offerings. For the nine months ended September 30, 2024, R&D expenses totaled $83.8 million, a slight decrease of 2.0% from $85.5 million in the same period of 2023.
Operational Highlights
The company achieved several key operational milestones, including FDA approvals for new indications and devices. In August 2024, Inspire received FDA approval for its next-generation Inspire system, expected to launch in 2025.
Liquidity Position
As of September 30, 2024, Inspire Medical Systems had cash, cash equivalents, and available-for-sale debt securities totaling $524.4 million, an increase from $469.5 million at the end of 2023. The company's working capital was $508.3 million, reflecting a decrease from the previous year.
| Metric | September 30, 2024 | December 31, 2023 |
|---|---|---|
| Cash and Cash Equivalents (in thousands) | $524,400 | $469,500 |
| Working Capital (in thousands) | $508,300 | $515,700 |
Market Trends and Future Outlook
Inspire Medical Systems is well-positioned for continued growth, with plans to expand into new markets and enhance its product portfolio. The company is actively working to increase its market penetration and address supply chain challenges that have historically impacted its operations.
A Who Owns Inspire Medical Systems, Inc. (INSP)
Major Shareholders
As of 2024, Inspire Medical Systems, Inc. (INSP) has a diverse ownership structure, predominantly held by institutional investors and company executives. The top shareholders include:
| Shareholder | Type of Ownership | Shares Owned | Percentage of Total Shares |
|---|---|---|---|
| The Vanguard Group, Inc. | Institutional Investor | 3,200,000 | 10.7% |
| BlackRock, Inc. | Institutional Investor | 2,500,000 | 8.4% |
| FMR LLC (Fidelity) | Institutional Investor | 2,000,000 | 6.7% |
| Inspire Medical Systems, Inc. (Insider Ownership) | Insider | 1,200,000 | 4.0% |
| Other Institutional Investors | Institutional Investor | 8,500,000 | 28.5% |
Executive Ownership
The executive team at Inspire Medical Systems holds a significant portion of the company’s shares, reflecting their commitment to the organization. Key executives and their respective shareholdings are as follows:
| Executive | Position | Shares Owned | Percentage of Total Shares |
|---|---|---|---|
| Timothy P. Herbert | President & CEO | 500,000 | 1.7% |
| Dr. R. Scott MacLeod | Chief Medical Officer | 250,000 | 0.8% |
| Brian M. Glick | Chief Financial Officer | 150,000 | 0.5% |
| Board of Directors | Various | 300,000 | 1.0% |
Institutional Ownership Trends
As of September 30, 2024, institutional ownership of Inspire Medical Systems, Inc. is approximately 60% of total shares outstanding. The following table summarizes the recent trends in institutional ownership:
| Period | Institutional Ownership Percentage | Change from Previous Period |
|---|---|---|
| Q1 2024 | 58.5% | +2.5% |
| Q2 2024 | 59.0% | +0.5% |
| Q3 2024 | 60.0% | +1.0% |
Ownership Structure Overview
Inspire Medical Systems has a total of approximately 29.96 million shares outstanding as of September 30, 2024. Below is the breakdown of ownership:
| Ownership Type | Number of Shares | Percentage of Total |
|---|---|---|
| Institutional Investors | 17,900,000 | 59.8% |
| Insider Ownership | 1,950,000 | 6.5% |
| Retail Investors | 10,110,000 | 33.7% |
Recent Developments
In August 2024, Inspire Medical Systems announced a share repurchase program authorized by its Board of Directors, allowing the company to repurchase up to $150 million of its common stock. As of September 30, 2024, no shares have been repurchased under this program.
Inspire Medical Systems, Inc. (INSP) Mission Statement
Corporate Vision
Inspire Medical Systems, Inc. aims to provide innovative solutions for the treatment of obstructive sleep apnea (OSA) through its Inspire therapy, which is a breakthrough approach to managing this condition. The company focuses on enhancing the quality of life for patients by offering effective treatment options that are less invasive than traditional methods.
Market Position
As of September 30, 2024, Inspire Medical Systems generated total revenue of $563.1 million for the nine months ended, representing a 30.3% increase from $432.3 million during the same period in 2023. The revenue growth was largely driven by increased sales of the Inspire system in the U.S., which accounted for 95.8% of total revenue, amounting to $539.4 million.
Mission Statement Overview
The mission of Inspire Medical Systems is to transform the treatment of sleep apnea and improve patient outcomes through:
- Innovative technology that provides a comfortable and effective therapy option.
- Commitment to research and development for continuous improvement of their Inspire system.
- Expansion of market access and awareness among healthcare providers and patients.
Financial Performance
For the three months ended September 30, 2024, the company reported:
- Revenue: $203.2 million, a 32.5% increase from $153.3 million in 2023.
- Gross Margin: 84.1% for both periods.
- Net Income: $18.5 million, compared to a net loss of $8.5 million for the same period in 2023.
| Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Revenue | $203.2 million | $153.3 million | +32.5% |
| Gross Margin | 84.1% | 84.1% | 0% |
| Net Income (Loss) | $18.5 million | $(8.5) million | +317.6% |
Research and Development Investment
Inspire Medical Systems has heavily invested in research and development, with R&D expenses totaling $83.8 million for the nine months ended September 30, 2024, a slight decrease from $85.5 million in the prior year. This investment is crucial for the advancement of their Inspire therapy and the development of new products.
Operational Strategy
The operational strategy of Inspire Medical Systems includes:
- Enhancing market penetration in existing centers.
- Expanding into new territories and centers.
- Increasing awareness among healthcare providers and patients regarding the benefits of Inspire therapy.
Global Reach
Revenue from outside the U.S. reached $23.7 million, a 52.3% increase from $15.5 million in 2023. This growth is attributed to the expansion of sales representatives in Europe and the initiation of reimbursed procedures in France.
Financial Summary
| Metric | 9 Months Ended Sept 30, 2024 | 9 Months Ended Sept 30, 2023 | Change |
|---|---|---|---|
| Revenue | $563.1 million | $432.3 million | +30.3% |
| Cost of Goods Sold | $87.0 million | $68.5 million | +27.0% |
| Gross Profit | $476.1 million | $363.8 million | +30.9% |
| Operating Expenses | $471.9 million | $413.3 million | +14.2% |
| Net Income (Loss) | $18.3 million | $(35.9) million | +150.9% |
Market Challenges
Despite strong growth, Inspire Medical Systems faces challenges including:
- Capacity constraints among ENT surgeons which may limit the pace of patient adoption.
- Supply chain disruptions that could affect inventory levels and product availability.
How Inspire Medical Systems, Inc. (INSP) Works
Business Overview
Inspire Medical Systems, Inc. (INSP) specializes in developing and commercializing innovative therapies for patients with obstructive sleep apnea (OSA). The company's primary product is the Inspire therapy, a surgically implanted device that stimulates the hypoglossal nerve to prevent airway obstruction during sleep.
Financial Performance
As of September 30, 2024, Inspire Medical Systems reported significant financial growth. The company generated revenue of $203.2 million for the three months ended September 30, 2024, compared to $153.3 million for the same period in 2023, marking a 32.5% increase. For the nine months ended September 30, 2024, total revenue was $563.1 million, up from $432.3 million in 2023, reflecting a 30.3% growth rate.
| Period | Revenue | Gross Profit | Net Income (Loss) | Gross Margin |
|---|---|---|---|---|
| Q3 2024 | $203.2 million | $170.8 million | $18.5 million | 84.1% |
| Q3 2023 | $153.3 million | $128.9 million | $(8.5) million | 84.1% |
| 9M 2024 | $563.1 million | $476.1 million | $18.3 million | 84.5% |
| 9M 2023 | $432.3 million | $363.8 million | $(35.9) million | 84.1% |
Revenue Breakdown
In the third quarter of 2024, revenue generated in the U.S. was $195.8 million, an increase of $48.3 million, or 32.8%, from the previous year. Revenue from international markets totaled $7.4 million, up 27.2% year-over-year.
| Region | Q3 2024 Revenue | Q3 2023 Revenue | Change | Percentage Change |
|---|---|---|---|---|
| United States | $195.8 million | $147.5 million | $48.3 million | 32.8% |
| All Other Countries | $7.4 million | $5.8 million | $1.6 million | 27.2% |
Cost Structure
The cost of goods sold for the three months ended September 30, 2024, was $32.4 million, up from $24.4 million in the same period of 2023, reflecting a 32.9% increase. The gross margin for Q3 2024 remained stable at 84.1%.
Operating Expenses
Research and development (R&D) expenses for the three months ended September 30, 2024, were $26.1 million, down from $29.1 million in Q3 2023. Selling, general and administrative (SG&A) expenses increased to $130.4 million from $113.2 million, a rise of 15.1%.
| Expense Category | Q3 2024 | Q3 2023 | Change | Percentage Change |
|---|---|---|---|---|
| Research and Development | $26.1 million | $29.1 million | $(3.0) million | (10.5%) |
| Selling, General and Administrative | $130.4 million | $113.2 million | $17.1 million | 15.1% |
Net Income
For the three months ended September 30, 2024, Inspire Medical Systems reported a net income of $18.5 million, compared to a net loss of $(8.5) million in Q3 2023. For the nine months ended September 30, 2024, net income was $18.3 million, recovering from a loss of $(35.9) million in the prior year.
Cash Flow and Liquidity
As of September 30, 2024, Inspire Medical Systems had cash and cash equivalents totaling $524.4 million, an increase from $469.5 million at the end of 2023. The net cash provided by operating activities for the nine months ended September 30, 2024, was $61.1 million.
| Cash Flow Category | 9M 2024 | 9M 2023 |
|---|---|---|
| Net Cash Provided by Operating Activities | $61.1 million | $7.4 million |
| Net Cash Used in Investing Activities | $(116.9) million | $(143.1) million |
| Net Cash Provided by Financing Activities | $17.7 million | $24.1 million |
Market Position and Future Outlook
Inspire Medical Systems continues to focus on expanding its market presence through direct-to-consumer marketing and increasing physician awareness. The company is also investing in R&D to enhance the Inspire therapy and develop new products such as the SleepSync™ programmer, expected to launch in late 2024.
How Inspire Medical Systems, Inc. (INSP) Makes Money
Revenue Generation
Inspire Medical Systems generates revenue primarily through the sales of its Inspire therapy system, which is designed to treat obstructive sleep apnea (OSA). For the nine months ended September 30, 2024, the company reported total revenue of $563.1 million, an increase of $130.8 million, or 30.3%, compared to $432.3 million for the same period in 2023. This growth was largely driven by increased market penetration and expansion into new territories.
| Period | Total Revenue (in millions) | U.S. Revenue (in millions) | International Revenue (in millions) | Growth Rate (%) |
|---|---|---|---|---|
| 9 Months Ended September 30, 2024 | $563.1 | $539.4 | $23.7 | 30.3 |
| 9 Months Ended September 30, 2023 | $432.3 | $416.7 | $15.5 | - |
Sales Breakdown by Region
During the nine months ended September 30, 2024, revenue generated in the U.S. accounted for 95.8% of total revenue, while international sales contributed 4.2%. The U.S. revenue increased by $122.7 million, or 29.4%, while international revenue grew by $8.1 million, or 52.3%.
| Region | 9 Months Ended September 30, 2024 | 9 Months Ended September 30, 2023 | Change ($ millions) | Change (%) |
|---|---|---|---|---|
| United States | $539.4 | $416.7 | $122.7 | 29.4 |
| All Other Countries | $23.7 | $15.5 | $8.1 | 52.3 |
Cost of Goods Sold and Gross Margin
For the nine months ended September 30, 2024, the cost of goods sold (COGS) was $87.0 million, reflecting a significant increase of $18.5 million, or 27.0%, compared to $68.5 million for the same period in 2023. Despite this increase, the gross margin improved to 84.5%, up from 84.1% in the previous year, primarily due to higher sales volume and manufacturing efficiencies.
| Metric | 9 Months Ended September 30, 2024 | 9 Months Ended September 30, 2023 | Change ($ millions) | Gross Margin (%) |
|---|---|---|---|---|
| Cost of Goods Sold | $87.0 | $68.5 | $18.5 | 84.5 |
Operating Expenses
Operating expenses for Inspire Medical Systems totaled $471.9 million for the nine months ended September 30, 2024, an increase of $58.6 million, or 14.2%, compared to $413.3 million for the same period in 2023. This increase was primarily driven by higher selling, general, and administrative (SG&A) expenses, which rose to $388.1 million, reflecting a growth of $60.2 million, or 18.4%.
| Operating Expense Category | 9 Months Ended September 30, 2024 (in millions) | 9 Months Ended September 30, 2023 (in millions) | Change ($ millions) |
|---|---|---|---|
| Research and Development | $83.8 | $85.5 | ($1.7) |
| Selling, General and Administrative | $388.1 | $327.9 | $60.2 |
Net Income
Inspire Medical Systems reported a net income of $18.3 million for the nine months ended September 30, 2024, compared to a net loss of $35.9 million for the same period in 2023. This marked a significant turnaround, reflecting improved revenue and operational efficiency.
| Period | Net Income (Loss) (in millions) |
|---|---|
| 9 Months Ended September 30, 2024 | $18.3 |
| 9 Months Ended September 30, 2023 | ($35.9) |
Market Strategy and Future Outlook
Inspire Medical Systems is focused on expanding its market presence through increased awareness of its Inspire therapy among physicians and patients. Additionally, the company is investing in research and development, including the launch of its next-generation Inspire system expected in 2025. The ongoing efforts to enter new markets, including additional European countries and the Asia Pacific region, are anticipated to contribute to future revenue growth.
Inspire Medical Systems, Inc. (INSP) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Inspire Medical Systems, Inc. (INSP) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Inspire Medical Systems, Inc. (INSP)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Inspire Medical Systems, Inc. (INSP)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.